Regeneron Pharmaceuticals (57) | Business Operations (8)

Browse by Subcategory

Recent Contracts

Modification P00006 to Supply Agreement, dated as of February 24, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on May 4, 2022)
First Amendment to Immuno-oncology License and Collaboration Agreement, dated as of October 6, 2021, by and between the Registrant and Sanofi Biotechnology SAS (Filed With SEC on February 7, 2022)
Amended and Restated Immuno-oncology Discovery and Development Agreement, executed on January 2, 2019 and effective as of December 31, 2018, by and between the Registrant and... (Filed With SEC on February 7, 2019)
Fourth Amendment to Amended and Restated License and Collaboration Agreement, dated as of October 6, 2021, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi (Filed With SEC on February 7, 2022)
Modification P00004 to Supply Agreement, dated as of July 26, 2021, by and between Regeneron Pharmaceuticals, Inc. (the "Registrant") and the U.S. Army Contracting Command, New... (Filed With SEC on November 4, 2021)
Modification P00005 to Supply Agreement, dated as of September 14, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 4, 2021)
Third Amendment to Amended and Restated License and Collaboration Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant, Sanofi... (Filed With SEC on August 5, 2020)
Form of Co-Co Collaboration Agreement (Exhibit B to Master Agreement contained in Exhibit 10.4) (Filed With SEC on August 6, 2019)